KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Work In Process (2016 - 2019)

Pfizer (PFE) has disclosed Work In Process for 11 consecutive years, with $5.2 billion as the latest value for Q1 2019.

  • On a quarterly basis, Work In Process rose 15.54% to $5.2 billion in Q1 2019 year-over-year; TTM through Mar 2019 was $5.2 billion, a 15.54% increase, with the full-year FY2018 number at $4.7 billion, up 20.29% from a year prior.
  • Work In Process was $5.2 billion for Q1 2019 at Pfizer, up from $4.7 billion in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $5.2 billion in Q1 2019 to a low of $3.4 billion in Q1 2015.
  • A 5-year average of $4.2 billion and a median of $4.0 billion in 2016 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: increased 21.06% in 2015, then dropped 6.0% in 2016.
  • Pfizer's Work In Process stood at $3.9 billion in 2015, then decreased by 6.0% to $3.7 billion in 2016, then increased by 5.74% to $3.9 billion in 2017, then grew by 20.29% to $4.7 billion in 2018, then increased by 10.23% to $5.2 billion in 2019.
  • Per Business Quant, the three most recent readings for PFE's Work In Process are $5.2 billion (Q1 2019), $4.7 billion (Q4 2018), and $4.8 billion (Q3 2018).